Durect corporation to announce third quarter 2023 financial results and provide a business update

Cupertino, calif. , nov. 9, 2023 /prnewswire/ -- durect corporation (nasdaq: drrx), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for the three months ended september 30, 2023 on monday, november 13, 2023.
DRRX Ratings Summary
DRRX Quant Ranking